How Digital Engagement Is Reshaping Life Sciences Commercial Strategy in MENA

As metabolic and obesity therapies reach global scale, commercial models across the Gulf and North Africa are shifting toward behavioural data, predictive segmentation and lifecycle-timed engagement — with consequences for healthcare investment, industrial policy and regional competitiveness.

Executive Summary

The global expansion of GLP-1 and obesity therapies has produced one of the fastest-growing pharmaceutical categories in recent years, and in doing so has exposed the limits of conventional commercial models. Research by IQVIA into the digital behaviour of healthcare professionals (HCPs) describes a clinical audience that researches continuously, reacts sharply to trial results and regulatory decisions, and concentrates a disproportionate share of its research activity among a small group of highly engaged prescribers. The implications for MENA extend well beyond obesity medicine. They point to a broader shift in how pharmaceutical and healthcare organisations measure demand, allocate commercial resources and time their engagement — and, by extension, to how Gulf and North African health systems, institutional investors and industrial planners should approach data infrastructure, local manufacturing and workforce capability. Awareness, once the central commercial goal, has become a weak differentiator in saturated therapeutic categories. Activation, conversion and adherence now carry more strategic weight. For a region investing heavily in healthcare capacity, digital government and economic diversification, that shift is not a marketing question. It is a question about where clinical intelligence sits in the value chain, and who controls it.

Introduction

The commercial architecture of the pharmaceutical industry was built for a world in which information was scarce. Physicians learned about new therapies through journals, conferences and sales representatives; brand awareness was a meaningful constraint on adoption; and reach was a reasonable proxy for effectiveness. In several therapeutic areas, that world no longer exists.

Obesity and metabolic disease illustrate the change most clearly. GLP-1 therapies have moved from specialist prescribing into mainstream clinical and cultural conversation, with awareness now effectively universal in many high-income markets. The competitive problem has inverted: instead of being unknown, products in this category compete for attention inside a saturated information environment where physicians are inundated with similar claims.

MENA markets sit at a different point on that curve, but the direction of travel is similar. Gulf health systems have expanded insurance coverage, invested in hospital capacity and digital health infrastructure, and adopted national transformation programmes that elevate preventive care and chronic disease management. As metabolic disease burdens rise across the region, the therapies at the centre of this global category become commercially relevant to MENA faster than most pharmaceutical categories historically have.

Main Analysis

A category that has outgrown traditional commercial playbooks

IQVIA's analysis of HCP digital behaviour identifies a marked pattern: engagement with GLP-1 and obesity topics spikes immediately after major clinical, regulatory or pricing developments. The publication of SURMOUNT-2 results, which reported approximately 15% weight loss for tirzepatide, triggered a surge in professional research activity. The resolution of a prolonged semaglutide supply shortage renewed interest by restoring access to a high-demand therapy. Later in 2025, further engagement peaks followed Most Favoured Nation pricing agreements that sharply reduced GLP-1 costs and extended Medicare coverage of obesity treatment, alongside the approval of the first oral GLP-1 weight-loss product.

The pattern matters because it demonstrates that clinical curiosity is event-driven and time-sensitive. Brands that engage weeks after a signal emerges are competing for attention that has already moved elsewhere. The commercial advantage increasingly belongs to organisations able to detect interest as it forms and respond within the same window.

The long tail of prescriber behaviour

The second structural feature identified in the research is distributional. HCP digital behaviour in obesity medicine follows a long-tail pattern: a small top decile of physicians generates a disproportionate share of research activity, while the majority engages only lightly. This is not simply a targeting detail. It reframes how commercial investment should be allocated — intensive, personalised engagement for high-intensity prescribers and researchers, and lighter-touch, well-structured content for the broader base whose needs are episodic rather than continuous.

IQVIA also notes the scale of the prescribing universe: more than 500,000 healthcare professionals wrote GLP-1 prescriptions in 2025 alone, against projections that as many as 30 million Americans could be eligible for or using such therapies by 2030. At that scale, conventional audience-quality metrics lose discriminating power. The analytical premium moves to down-funnel indicators — activation, conversion, switching and adherence — that reflect actual behavioural movement rather than exposure.

Lifecycle as a commercial variable

The research draws a firm distinction between pre-launch and in-market strategy. Pipeline products benefit from intent modelling that identifies early adopters and shapes educational content around their specific clinical concerns; marketed products require competitive intelligence, monitoring of competitor trial activity and molecule mentions, and rapid deployment of comparative data or patient-support resources. Timing and sequence — touchpoints before, during and after high-attention events — become as important as message content.

The analysis also flags an emerging distribution channel consideration that is relevant well beyond this category: content must be structured for discovery by AI-driven search tools, which are increasingly the first point of contact between clinicians and medical information. In practical terms, that means machine-readable structure, clear attribution and formatting discipline are becoming part of commercial publishing standards rather than technical afterthoughts.

What MENA's data environment still needs

The operational requirements implied by this model — granular prescriber-level data, longitudinal behavioural tracking, predictive modelling and rapid content deployment — depend on data infrastructure that is uneven across MENA. Gulf markets have advanced digital health records, national health data platforms and relatively mature governance frameworks, which make behavioural analytics feasible. North African markets are more fragmented, with data sitting across public systems, private providers and informal channels.

That divergence has commercial consequences. Regional commercial hubs, clinical research capacity and data-analytics functions tend to concentrate where data quality and regulatory certainty are highest. Countries that build credible health-data governance — covering consent, interoperability and cross-border data transfer — are better positioned to attract the analytical and commercial functions that now sit at the centre of pharmaceutical strategy, rather than only the sales activity that previously defined regional presence.

Regional Impact

The shift toward behavioural and predictive commercial models carries several implications for the region:

• Health system efficiency. Real-time prescribing intelligence can support more precise procurement forecasting, particularly for high-cost chronic disease therapies where supply volatility has proven disruptive. Gulf payers investing in value-based care stand to gain from the same data infrastructure that industry uses commercially.
• Industrial development. Localisation of pharmaceutical manufacturing across the region depends on reliable demand signals. Behavioural analytics that clarify adoption curves and prescriber concentration reduce the planning risk attached to new production capacity, particularly for injectable and biosimilar formats.
• Capital allocation. Healthcare has become a core allocation theme for Gulf sovereign and private investors. The differentiation between healthcare assets increasingly rests on data capability — whether providers, distributors or diagnostics platforms can generate structured clinical and behavioural insight.
• Employment and human capital. Demand grows for data scientists, health economists, regulatory specialists and medical affairs professionals able to work with behavioural datasets. This is a skills category where regional supply remains thin relative to ambition.
• Cross-border trade and supply chains. Greater visibility into clinical demand supports more resilient import and distribution planning, an area where MENA markets have been exposed to global supply disruptions in high-demand therapeutic categories.
• Regional integration. Shared data standards and mutual recognition of regulatory evidence would allow smaller markets to participate in analytics-driven commercial models that currently require scale to justify.
• Competitiveness and business confidence. Markets with clear rules on health data and digital therapeutics are likely to attract disproportionate multinational commercial and research investment relative to those without them.

Strategic Implications

For executives. The competitive question in high-growth therapeutic categories is no longer reach but timing. Commercial teams operating in MENA should assess whether their regional data infrastructure can support event-triggered engagement, and whether content is structured for discovery through AI-assisted search as well as traditional channels.

For investors. Healthcare assets should be evaluated on data capability as well as clinical capacity. Diagnostics networks, digital health platforms, contract research organisations and distribution businesses that generate structured prescribing and outcomes data occupy a more strategic position than their revenue multiples alone suggest.

For policymakers. Health data governance is becoming industrial policy. Frameworks that enable secure, interoperable and cross-border data flows support both patient outcomes and the attraction of commercial, research and analytical functions. Restrictive or ambiguous rules push those functions elsewhere.

For market participants. The most immediate opportunities are likely to sit in analytics infrastructure, medical affairs capability, regulatory and market-access advisory, and clinical education platforms that serve specialist communities. Competitive risk lies in over-reliance on broad awareness spending in categories where awareness is already saturated, and in underinvestment in the data foundations that make targeted engagement possible.

Geopolitical considerations. Global pricing decisions and regulatory actions in major markets transmit quickly into MENA commercial strategy. Reference pricing, reimbursement decisions and supply allocation choices made in the United States and Europe shape availability and affordability across the region, often with limited regional consultation.

Future Outlook

Over the next three to five years, several developments appear plausible:

• Metabolic disease becomes a regional health-system priority. Rising prevalence, expanded insurance coverage and the arrival of oral formulations are likely to push obesity and diabetes management higher on national health agendas across the Gulf and parts of North Africa, with corresponding pressure on reimbursement design.
• Analytics capability becomes a locational factor. Commercial, medical affairs and data functions will gravitate toward markets with strong health-data governance, rather than following the historical pattern of distribution-led regional presence.
• Life sciences localisation meets data localisation. Manufacturing initiatives and health-data frameworks will increasingly be discussed as a single investment proposition, since both depend on demand visibility.
• AI-mediated information discovery reshapes medical communication. As clinicians increasingly begin research through AI-assisted tools, content structure and verifiability become commercial prerequisites, favouring organisations with disciplined publishing operations.
• Capital markets follow the theme. Healthcare and health-technology listings, private equity and venture activity in the region are likely to concentrate on businesses with proprietary data assets rather than purely service-based models.
• Regional divergence persists. Gulf markets are positioned to move faster on analytics-driven models; North African markets will depend on regulatory harmonisation, infrastructure investment and public-private coordination to participate at similar depth.

Conclusion

The digital engagement patterns documented in IQVIA's research describe a clinical audience that is attentive, event-driven and highly concentrated. That behavioural profile is not unique to obesity medicine; it is a preview of how commercial engagement is likely to function in an increasing number of therapeutic categories as information becomes abundant and attention becomes the scarce resource.

For MENA, the strategic question is structural. Markets that treat health data as infrastructure — governed clearly, invested in deliberately and connected across borders — will be positioned to host the analytical, commercial and industrial activity that this model requires. Those that do not will remain consumers of intelligence generated elsewhere. In a region where healthcare is central to both social policy and diversification strategy, that distinction is likely to matter more than any single product cycle.

Key Takeaways

• Awareness has become a weak commercial differentiator in high-growth therapeutic categories; activation, conversion and adherence carry greater strategic value.
• HCP research activity is event-driven and concentrated in a small share of highly engaged prescribers, which favours real-time, targeted engagement over broad campaigns.
• Commercial models now depend on granular behavioural data, predictive segmentation and lifecycle-specific timing — capabilities that require robust health-data infrastructure.
• For MENA, health data governance and interoperability are effectively industrial policy, influencing where commercial, research and manufacturing investment locates.
• Investment attention is likely to shift toward assets with proprietary clinical and behavioural data, spanning diagnostics, digital health, contract research and distribution.
• North African markets risk falling behind Gulf peers without regulatory harmonisation, infrastructure investment and coordinated public-private data frameworks.

SEO Keywords

MENA Economy, Middle East Business, North Africa Economy, MENA Investment, Foreign Direct Investment, Economic Diversification, Digital Economy, Healthcare Investment MENA, Life Sciences MENA, Market Intelligence, Policy & Regulation, Strategic Investment, Capital Markets, Sovereign Wealth Funds, Supply Chain, Business Intelligence, Regional Competitiveness, Digital Health, Cross-Border Trade

Sources

• IQVIA. "HCP Digital: Using the Digital World as an Advantage." https://www.iqvia.com/locations/united-states/blogs/2026/03/hcp-digital-using-the-digital-world-as-an-advantage
• J.P. Morgan Global Research. Obesity drug market projections cited in the IQVIA analysis. https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
• Eli Lilly and Company. SURMOUNT-2 results published in The Lancet. https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-2-results-published-lancet-show-tirzepatide